Our patented technology

The process starts with the collection of plasma samples of the disease under study and appropriate control samples followed by the removal of the most abundant plasma proteins to produce a natural complex antigen mix. Hybridoma antibody libraries are then generated and clones that differentially detect epitopes between plasma samples from patients and controls detected in a competition ELISA screening assay . Following further qualification, the selected clones are assembled into epitope-specific libraries for the development of diagnostic assays and clinical testing.